{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T12:47:18Z","timestamp":1780836438456,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13318-022-00768-7","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T11:04:35Z","timestamp":1650452675000},"page":"537-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects"],"prefix":"10.1007","volume":"47","author":[{"given":"Jie","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"768_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"768_CR2","doi-asserted-by":"publisher","first-page":"14S","DOI":"10.1111\/1523-1747.ep12386079","volume":"102","author":"GG Krueger","year":"1994","unstructured":"Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol. 1994;102:14S-18S.","journal-title":"J Invest Dermatol"},{"key":"768_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"W-H Boehncke","year":"2015","unstructured":"Boehncke W-H, Sch\u00f6n MP. Psoriasis. Lancet Lond Engl. 2015;386:983\u201394.","journal-title":"Lancet Lond Engl."},{"key":"768_CR4","doi-asserted-by":"crossref","unstructured":"Sakkas LI, Zafiriou E, Bogdanos DP. Mini review: new treatments in psoriatic arthritis. Focus on the IL-23\/17 axis. Front Pharmacol. 2019;10:872. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6691125\/.","DOI":"10.3389\/fphar.2019.00872"},{"key":"768_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0733-8635(05)70376-4","volume":"14","author":"J Koo","year":"1996","unstructured":"Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485\u201396.","journal-title":"Dermatol Clin"},{"key":"768_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40495-019-00180-x","volume":"5","author":"Y Xu","year":"2019","unstructured":"Xu Y, Sharma A, Chen Y, Zhou H. What we can learn from current inflammatory bowel disease (IBD) biological therapy\u2014dose regimen and others. Curr Pharmacol Rep. 2019;5:115\u201330.","journal-title":"Curr Pharmacol Rep."},{"key":"768_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/jmg.2007.053595","volume":"45","author":"N Wolf","year":"2008","unstructured":"Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet. 2008;45:114\u20136.","journal-title":"J Med Genet"},{"key":"768_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","volume":"16","author":"AR Moschen","year":"2019","unstructured":"Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185\u201396.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"768_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1600-065X.2008.00700.x","volume":"226","author":"L Lyakh","year":"2008","unstructured":"Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F. Regulation of interleukin-12\/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev. 2008;226:112\u201331.","journal-title":"Immunol Rev"},{"key":"768_CR10","unstructured":"Janssen Biotech Inc. Stelara (Ustekinumab) United States Package Insert. Horsham, PA: Janssen Biotech Inc.; 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761044s008lbl.pdf. Cited 15 Mar 2022."},{"key":"768_CR11","doi-asserted-by":"publisher","first-page":"P9","DOI":"10.1016\/j.clpt.2003.11.034","volume":"75","author":"YW Zhu","year":"2004","unstructured":"Zhu YW, Zhang J, Pendley C, Frederick B, Mascelli M, Gottleib AB, et al. Pharmacokinetics of a human monoclonal antibody to IL-12 P40 following single intravenous infusion in patients with moderate to severe plaque-type psoriasis. Clin Pharmacol Ther. 2004;75:P9\u2013P9.","journal-title":"Clin Pharmacol Ther"},{"key":"768_CR12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1185\/030079907X182112","volume":"23","author":"AB Gottlieb","year":"2007","unstructured":"Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, Frederick B, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12\/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007;23:1081\u201392.","journal-title":"Curr Med Res Opin"},{"key":"768_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0091270008329556","volume":"49","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49:162\u201375.","journal-title":"J Clin Pharmacol"},{"key":"768_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.5414\/CPP48830","volume":"48","author":"YW Zhu","year":"2010","unstructured":"Zhu YW, Mendelsohn A, Pendley C, Davis HM, Zhou H. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. Int J Clin Pharmacol Ther. 2010;48:830\u201346.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"768_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10928-017-9529-x","volume":"44","author":"C Hu","year":"2017","unstructured":"Hu C, Adedokun OJ, Chen Y, Szapary PO, Gasink C, Sharma A, et al. Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn\u2019s disease. J Pharmacokinet Pharmacodyn. 2017;44:425\u201336.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"768_CR16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/jcph.1582","volume":"60","author":"Y Xu","year":"2020","unstructured":"Xu Y, Hu C, Chen Y, Miao X, Adedokun OJ, Xu Z, et al. Population pharmacokinetics and exposure-response modeling analyses of ustekinumab in adults with moderately to severely active ulcerative colitis. J Clin Pharmacol. 2020;60:889\u2013902.","journal-title":"J Clin Pharmacol"},{"key":"768_CR17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet Lond Engl. 2013;382:780\u20139.","journal-title":"Lancet Lond Engl."},{"key":"768_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, et al. Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000\u20136.","journal-title":"Ann Rheum Dis"},{"key":"768_CR19","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314.","journal-title":"N Engl J Med"},{"key":"768_CR20","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/bjd.15722","volume":"177","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, et al. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). Br J Dermatol. 2017;177:1552\u201361.","journal-title":"Br J Dermatol"},{"key":"768_CR21","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360.","journal-title":"N Engl J Med"},{"key":"768_CR22","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","volume":"154","author":"OJ Adedokun","year":"2018","unstructured":"Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn\u2019s disease. Gastroenterology. 2018;154:1660\u201371.","journal-title":"Gastroenterology"},{"key":"768_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/jcph.1101","volume":"58","author":"Y Xu","year":"2018","unstructured":"Xu Y, Hu C, Zhuang Y, Hsu B, Xu Z, Zhou H. Confirmatory population pharmacokinetic analysis for sirukumab, a human monoclonal antibody targeting interleukin-6, in patients with moderately to severely active rheumatoid arthritis. J Clin Pharmacol. 2018;58:939\u201351.","journal-title":"J Clin Pharmacol"},{"key":"768_CR24","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645\u201368.","journal-title":"J Pharm Sci"},{"key":"768_CR25","doi-asserted-by":"crossref","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development\u2014part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol. 2013;2:e38.","DOI":"10.1038\/psp.2013.14"},{"key":"768_CR26","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/j.0022-202X.2004.23448.x","volume":"123","author":"CL Kauffman","year":"2004","unstructured":"Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123:1037\u201344.","journal-title":"J Invest Dermatol"},{"key":"768_CR27","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","volume":"21","author":"S Sharma","year":"2015","unstructured":"Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, et al. Pharmacokinetics and exposure\u2013efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn\u2019s disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21:783\u201392.","journal-title":"Inflamm Bowel Dis"},{"key":"768_CR28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6:576\u201388.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"768_CR29","doi-asserted-by":"publisher","unstructured":"Dirks NL. Population pharmacokinetics of therapeutic monoclonal antibodies: examples and estimation method performance differences. Theses and dissertations (ETD), paper 63. Memphis, TN: University of Tennessee Health Science Center; 2010. Available from: https:\/\/doi.org\/10.21007\/etd.cghs.2010.0072","DOI":"10.21007\/etd.cghs.2010.0072"},{"key":"768_CR30","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet Lond Engl. 2008;371:1665\u201374.","journal-title":"Lancet Lond Engl."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00768-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-022-00768-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00768-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T03:37:37Z","timestamp":1656128257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-022-00768-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s13318-022-00768-7","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"16 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Janssen Research & Development, LLC., Pharmaceutical Companies of Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors received no financial support in the writing of this manuscript. All the authors are employees of Janssen Research & Development, LLC, Pharmaceutical Companies of Johnson & Johnson at the time of the study and may own stock and\/or stock options in the company. The opinions expressed in this article are those of the authors and not necessarily those of the company that employs them.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in the studies involved in the analysis were in accordance with the 1964 Helsinki Declaration (and its amendments), and the details of the ethics committee or institutional review board which approved the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent before any study-related procedures were performed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent that they approve the manuscript for submission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. is available at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"JS and YX conceived and planned the analysis. JS compiled the dataset and conducted the modeling analysis. All authors contributed to the interpretation of results and the writing of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}